Munich Cancer Registry

Munich Cancer Registry at Munich Cancer Center
Marchioninistr. 15
Munich, 81377
Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Baseline statistics

C01: Base of tongue cancer

Year of diagnosis	1998-2011
Patients	550
Diseases	551
Creation date	04/02/2013
Export date	01/03/2013
Population	4.5 m

BERLIN

GERMANY

BAVARIA

MUNICH

Global Statements about the statistics on the Internet –
Baseline Statistics (grey button ▭), Survival (red button ▬)

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut[#], with a total of 4.5 million inhabitants, account for the frequency of cancer diseases[##] and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases[###] are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR. The time-delayed acquisition of data and the occasionally high DCO-rates indicate optimizing reserves, among others, because of current financial and legal conditions that hinder the analyses.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, April 2013

[#]   Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.51 million to 3.96 in 2002, and to 4.52 million in 2007). Death certificates from 2011 are incorporated into these analyses.

[##] Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.

[###] DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate. A high proportion of DCO cases (≥5%) in particular cancer types indicate insufficient participation of specific cancer specializations.

Some remarks regarding this cancer type

As a general rule, these few results from the TRM form the basis of sophisticated analyses. For head and neck tumors this is not the case. Therefore the results for head and neck tumors should be interpreted with caution. In part this is due to problems of classification because of limited specific details of locality. Additionally, with advanced tumors in a close topographic location it is often not possible to determine the exact ICD localization of a tumor.

ICD-O-3 codes (topography) used for specifying cancer site

ICD-O-3	Description
C01.9	Base of tongue (posterior third of tongue, root of tongue)

INCIDENCE

Table 1

Patient cohorts by year of diagnosis including DCO cases
and multiple primaries, and with proportion of deaths and active follow-up

Year of diagnosis	Cases # n	DCO cases n	Prop. DCO %	Prop. mult. primaries %	Prop. deaths %	Prop. actively followed %
1998	14			21.4	71.4	100.0
1999	22			36.4	90.9	100.0
2000	13	1	7.7	38.5	76.9	100.0
2001	19	2	10.5	31.6	84.2	100.0
2002	34			17.6	67.6	97.1
2003	42	5	11.9	54.8	83.3	100.0
2004	48	4	8.3	20.8	75.0	93.8
2005	53	3	5.7	30.2	54.7	94.3
2006	51	1	2.0	27.5	60.8	96.1
2007	52	1	1.9	26.9	61.5	82.7 ##
2008	51	4	7.8	19.6	58.8	84.3
2009	44			25.0	43.2	90.9
2010	54	1	1.9	25.9	46.3	92.6
2011	54	2	3.7	18.5	27.8	68.5 ###
1998-2011	551	24	4.4	27.2	60.1	90.7

\#   The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

\##   Since 2007 the percentage of actively followed patients sharply declined compared to the previous years. This is a consequence of ambiguous data protection rules that currently forbid cancer registries in Bavaria to obtain the essential life status informations from competent registration offices.

\###   Please be aware that data of recent annual patient cohorts may not yet be fully processed. Therefore, the presented figures and tables are potentially related to different time periods as pointed out in the respective headlines or legends.

Table 1a

Patient cohorts by year of diagnosis and gender
including DCO cases

Year of diagnosis	All n	Males n	Females n	Prop. males %
1998	14	10	4	71.4
1999	22	18	4	81.8
2000	13	9	4	69.2
2001	19	12	7	63.2
2002	34	27	7	79.4
2003	42	37	5	88.1
2004	48	33	15	68.8
2005	53	40	13	75.5
2006	51	38	13	74.5
2007	52	42	10	80.8
2008	51	40	11	78.4
2009	44	29	15	65.9
2010	54	38	16	70.4
2011	54	42	12	77.8
1998-2011	551	415	136	75.3

Table 2

Incidence measures by year of diagnosis and gender including DCO cases
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.52 m as of 2007, respectively)

Year of diagnosis	Males n	Females n	Males Inc. raw	Fem. Inc. raw	Males Inc. WS	Fem. Inc. WS	Males Inc. ES	Fem. Inc. ES	Males Inc. BRD-S	Fem. Inc. BRD-S
1998	10	4	0.9	0.3	0.6	0.2	0.8	0.2	0.9	0.3
1999	18	4	1.6	0.3	1.1	0.2	1.4	0.3	1.5	0.3
2000	9	4	0.8	0.3	0.5	0.2	0.7	0.3	0.9	0.3
2001	12	7	1.0	0.6	0.7	0.3	1.0	0.4	1.1	0.5
2002	27	7	1.4	0.4	1.0	0.2	1.3	0.3	1.4	0.3
2003	37	5	2.0	0.3	1.2	0.1	1.7	0.2	2.0	0.2
2004	33	15	1.8	0.8	1.0	0.4	1.4	0.6	1.6	0.7
2005	40	13	2.1	0.7	1.4	0.3	1.9	0.5	2.1	0.6
2006	38	13	2.0	0.6	1.2	0.4	1.7	0.5	1.9	0.6
2007	42	10	1.9	0.4	1.2	0.3	1.7	0.4	1.8	0.4
2008	40	11	1.8	0.5	1.1	0.3	1.5	0.4	1.8	0.4
2009	29	15	1.3	0.6	0.8	0.3	1.1	0.5	1.3	0.5
2010	38	16	1.7	0.7	1.0	0.3	1.4	0.5	1.6	0.6
2011	42	12	1.9	0.5	1.1	0.3	1.5	0.4	1.7	0.4
1998-2011	415	136	1.7	0.5	1.0	0.3	1.4	0.4	1.6	0.5

The computation of the incidence measures includes all primaries, irrespective of first or subsequent malignancy.

Table 3

Age distribution parameters by year of diagnosis (All)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	14	57.7	13.2	31.1	78.2	44.9	50.3	58.0	67.5	77.8
1999	22	58.6	9.0	40.4	74.9	48.5	52.2	59.7	64.3	70.5
2000	13	60.3	14.0	35.9	78.3	42.5	47.6	65.5	68.7	78.2
2001	19	63.2	13.6	48.6	92.5	49.0	50.6	61.3	71.2	85.1
2002	34	60.4	8.9	43.8	81.5	50.3	54.8	58.2	65.1	72.1
2003	42	63.1	9.1	45.1	83.3	52.1	56.0	62.7	69.4	76.9
2004	48	63.8	10.0	38.6	93.3	52.0	58.5	62.6	69.7	75.4
2005	53	61.3	13.4	4.1	87.2	50.1	54.8	61.1	65.9	78.5
2006	51	60.3	12.0	19.0	84.8	46.0	52.6	60.1	68.0	76.2
2007	52	57.9	9.7	35.2	76.9	45.0	53.5	58.0	63.7	69.5
2008	51	64.2	10.2	38.3	87.7	51.7	58.7	63.6	71.1	77.4
2009	44	63.4	10.3	36.7	87.3	51.7	57.1	62.9	72.2	75.7
2010	54	64.6	11.4	38.0	92.1	50.1	57.6	65.6	72.7	77.9
2011	54	64.5	11.5	40.0	93.8	49.9	55.9	63.9	72.0	78.3
1998-2011	551	62.1	11.1	4.1	93.8	48.6	55.2	61.5	69.4	76.5

Table 3a

Age distribution parameters by year of diagnosis (MALES)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	10	57.3	10.8	44.9	78.2	46.1	50.3	54.9	60.4	75.2
1999	18	56.9	8.8	40.4	72.5	43.1	50.5	58.4	63.4	70.5
2000	9	59.7	15.8	35.9	78.3	35.9	47.6	59.2	73.3	78.3
2001	12	61.1	12.1	48.6	85.1	49.0	50.4	59.2	68.2	78.7
2002	27	59.7	8.2	43.8	80.2	48.0	54.6	58.2	64.2	70.8
2003	37	62.3	8.9	45.1	83.3	50.6	56.0	62.4	66.7	76.9
2004	33	62.9	8.8	38.6	80.3	54.8	58.9	62.5	68.3	72.5
2005	40	59.5	14.1	4.1	87.1	46.3	52.9	59.8	65.6	78.2
2006	38	61.0	10.5	38.7	84.8	46.7	54.4	60.1	66.8	77.4
2007	42	58.8	9.5	37.1	76.9	45.6	55.5	58.9	64.5	69.5
2008	40	64.4	9.3	38.3	85.9	53.8	59.9	63.2	71.1	77.7
2009	29	62.1	10.2	36.7	77.3	48.0	56.6	61.9	70.7	76.2
2010	38	63.8	12.4	38.0	92.1	49.5	54.0	63.9	72.7	81.3
2011	42	63.9	11.1	40.0	86.5	49.9	54.8	64.1	71.8	77.5
1998-2011	415	61.5	10.7	4.1	92.1	48.6	54.8	61.1	68.4	76.3

Table 3b

Age distribution parameters by year of diagnosis (FEMALES)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	4	58.8	20.0	31.1	77.8	31.1	45.0	63.2	72.6	77.8
1999	4	66.1	6.6	59.0	74.9	59.0	61.6	65.3	70.6	74.9
2000	4	61.8	10.6	46.0	68.2	46.0	55.7	66.5	67.9	68.2
2001	7	66.8	16.2	50.2	92.5	50.2	50.6	63.0	83.0	92.5
2002	7	63.3	11.4	50.3	81.5	50.3	55.2	58.3	73.9	81.5
2003	5	68.8	9.6	53.1	77.3	53.1	68.5	69.4	75.7	77.3
2004	15	66.0	12.3	48.0	93.3	50.3	57.0	63.1	75.2	81.4
2005	13	66.9	9.3	57.1	87.2	57.2	60.9	64.4	72.9	79.3
2006	13	58.1	15.9	19.0	76.4	45.9	48.1	65.4	70.1	71.3
2007	10	53.9	10.1	35.2	70.5	40.1	47.5	55.1	61.3	66.3
2008	11	63.7	13.4	45.6	87.7	49.7	51.5	64.5	76.3	77.4
2009	15	66.0	10.4	45.8	87.3	54.2	57.8	66.8	72.6	75.1
2010	16	66.5	8.7	47.1	77.9	53.4	60.6	67.8	73.2	77.8
2011	12	66.5	13.2	48.6	93.8	55.9	57.1	62.3	75.1	84.0
1998-2011	136	64.0	12.2	19.0	93.8	48.6	57.1	64.8	72.2	77.8

Table 4

Age distribution by 5-year age group and gender for period 1998-2011
(incl. DCO)

Age at diagnosis Years	Cases n	%	Cum.%	Males n	%	Cum.%	Females n	%	Cum.%
0-4	1	0.2	0.2	1	0.2	0.2			0.0
5-9	0	0.0	0.2			0.2			0.0
10-14	0	0.0	0.2			0.2			0.0
15-19	1	0.2	0.4			0.2	1	0.7	0.7
20-24	0	0.0	0.4			0.2			0.7
25-29	0	0.0	0.4			0.2			0.7
30-34	1	0.2	0.5			0.2	1	0.7	1.5
35-39	11	2.0	2.5	10	2.4	2.7	1	0.7	2.2
40-44	14	2.5	5.1	14	3.4	6.0			2.2
45-49	38	6.9	12.0	24	5.8	11.8	14	10.3	12.5
50-54	68	12.3	24.3	58	14.0	25.8	10	7.4	19.9
55-59	101	18.3	42.6	78	18.8	44.6	23	16.9	36.8
60-64	105	19.1	61.7	87	21.0	65.5	18	13.2	50.0
65-69	81	14.7	76.4	56	13.5	79.0	25	18.4	68.4
70-74	56	10.2	86.6	38	9.2	88.2	18	13.2	81.6
75-79	48	8.7	95.3	33	8.0	96.1	15	11.0	92.6
80-84	14	2.5	97.8	10	2.4	98.6	4	2.9	95.6
85+	12	2.2	100.0	6	1.4	100.0	6	4.4	100.0
All ages	551	100.0		415	100.0		136	100.0	

Included in the statistics are 36.7% multiple primaries in males and 32.4% in females.

Table 5

Age-specific incidence, DCO rate and proportion of all cancers
for period 1998-2011

Age at diagnosis Years	Males n	Females n	Males Age-spec. incid.	Females Age-spec. incid.	Males DCO rate n=18 %	Females DCO rate n=6 %	Males Prop.all cancers n=132509 %	Females Prop.all cancers n=129521 %
0- 4	1		0.1	0.0			0.4	
5- 9			0.0	0.0				
10-14			0.0	0.0				
15-19		1	0.0	0.1				0.4
20-24			0.0	0.0				
25-29			0.0	0.0				
30-34		1	0.0	0.1				0.1
35-39	10	1	0.5	0.0			0.5	0.0
40-44	14		0.6	0.0			0.5	
45-49	24	14	1.2	0.7	4.2		0.5	0.2
50-54	58	10	3.5	0.6	1.7		0.8	0.1
55-59	78	23	5.0	1.4	3.8	4.3	0.6	0.2
60-64	87	18	5.7	1.1	2.3		0.5	0.1
65-69	55	25	4.0	1.7	7.3		0.2	0.2
70-74	38	18	3.7	1.5	5.3	5.6	0.2	0.1
75-79	33	15	4.9	1.5	12.1	13.3	0.2	0.1
80-84	10	4	2.5	0.5			0.1	0.0
85+	6	6	2.2	0.8	16.7	33.3	0.1	0.0
All ages	414	136			4.3	4.4	0.3	0.1

Incidence		
Raw	1.6	0.5
WS	1.0	0.3
ES	1.4	0.4
BRD-S	1.6	0.5

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).

Table 6a

Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of second primaries
for period 1998-2011
MALES

Diagnosis	Observed n	Expected n	SIR	LCL 95%	UCL 95%		EAR	DCO %
C03-C06 Oral cavity	3	0.1	24.7	5.1	72.1	#	36.1	
C09-C10 Oropharynx	2	0.2	12.0	1.5	43.5	#	23.0	
C12-C13 Hypopharynx	2	0.1	21.9	2.7	79.2	#	24.0	
C15 Oesophagus	4	0.2	19.1	5.2	48.9	#	47.6	25.0
C18 Colon	2	0.9	2.2	0.3	7.9		13.6	
C19-C20 Rectum	2	0.6	3.3	0.4	11.8		17.4	
C22 Liver	2	0.3	7.1	0.9	25.8		21.6	50.0
C32 Larynx	3	0.1	22.6	4.7	66.1	#	36.0	66.7
C33-C34 Lung	10	1.2	8.0	3.8	14.7	#	109.8	10.0
C61 Prostate	2	2.8	0.7	0.1	2.6		-10.2	
C64 Kidney	3	0.4	8.0	1.7	23.4	#	32.9	
C91-C96 Leukaemia	2	0.1	14.8	1.8	53.3	#	23.4	
Other primaries	5	1.2	4.2	1.4	9.9	#	47.9	
Not observed	0	1.8	0.0	0.0	2.0		-23.1	
All mult. primaries	42	10.1	4.1	3.0	5.6	#	399.9	11.9

|	
Patients	306
Mean age at second malignancy (years)	63.4
Person-years	797
Mean observation time (years)	2.6
Median observation time (years)	1.5

The occurrence of second malignancy is statistically significant.

Observed second primaries with count 1 are pooled in category "Other primaries".

Table 6b

Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of second primaries
for period 1998-2011
FEMALES

Diagnosis	Observed n	Expected n	SIR	LCL 95%	UCL 95%		EAR	DCO %
C15 Oesophagus	2	0.0	107.4	13.0	387.8	#	61.2	
C33-C34 Lung	5	0.3	20.0	6.5	46.6	#	146.8	40.0
C50 Breast	2	1.1	1.8	0.2	6.6		28.0	50.0
C53 Cervix uteri	2	0.0	42.4	5.1	153.1	#	60.3	
Other primaries	5	0.3	15.6	5.1	36.4	#	144.6	
Not observed	0	1.8	0.0	0.0	2.1		-55.0	
All mult. primaries	16	3.5	4.6	2.6	7.4	#	385.8	18.8

```
Patients                                97
Mean age at second malignancy (years)   71.0
Person-years                            324
Mean observation time (years)           3.3
Median observation time (years)         2.4
```

The occurrence of second malignancy is statistically significant.

Observed second malignancy with count 1 are pooled in category "Other primaries".

C01: Malignant neoplasm of base of tongue
Age distribution and age-specific incidence 1998 - 2011 (Males: 414, Females: 136)

Figure 7. Age distribution and age-specific incidence

C01: Malignant neoplasm of base of tongue
### Age-specific incidence in international comparison

Figure 7a. Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).

Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2012, based on the November 2011 submission. http://www.seer.cancer.gov.

C01: Malignant neoplasm of base of tongue
Cumulative follow-up years since diagnosis for period 1998 - 2011 (excl. DCO)

Gender	n	Target Sum	Median	Actual Sum	Median
All patients					
Males	288	856	1.8	811	1.7
Females	96	358	2.6	337	2.6
Patients alive					
Males	129	579	4.1	534	3.7
Females	53	272	4.5	250	4.2

Figure 8. Cumulative follow-up years depending on time since diagnosis

The increase of the lost to follow-up rate can be interpreted as a consequence of a declining number of survivors over time.

Average incidence (world standard population) 2003 - 2008: Males

Average incidence (world standard population) 2003 - 2008: Females

Figure 9a. Map of cancer incidence (world standard population, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual incidence rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 1.2/100,000 WS N=218, females 0.3/100,000 WS N=65). Since cancer data are not available in some counties until 2007, the local incidence rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women were identified with newly diagnosed base of tongue cancer. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 0.2/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 1.3/100,000.

Standardized incidence ratio (SIR) 2003 - 2008: Males

Standardized incidence ratio (SIR) 2003 - 2008: Females

Figure 9b. Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SIR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=218, females N=65). Since cancer data are not available in some counties until 2007, the local SIR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women were identified with newly diagnosed base of tongue cancer. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 0.50. Though, the value of this parameter may vary with an underlying probability of 99% between 0.00 and 3.73, and is therefore not statistically striking.

MORTALITY

Table 10a

Patient cohorts of incident cancers by year of diagnosis, follow-up status,
proportion of DCO, deaths among the annual cohorts,
and proportion of available death certificates
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.52 m as of 2007, respectively)

Year of diagnosis	Incident cases n	Prop. actively followed %	Prop. DCO %	Deaths n	Prop. deaths %	Prop. deaths with death certific. %
1998	14	100.0		10	71.4	100.0
1999	22	100.0		20	90.9	90.0
2000	13	100.0	7.7	10	76.9	100.0
2001	19	100.0	10.5	16	84.2	93.8
2002	34	97.1		23	67.6	95.7
2003	42	100.0	11.9	35	83.3	94.3
2004	48	93.8	8.3	36	75.0	100.0
2005	53	94.3	5.7	29	54.7	100.0
2006	51	96.1	2.0	31	60.8	96.8
2007	52	82.7	1.9	32	61.5	100.0
2008	51	84.3	7.8	30	58.8	100.0
2009	44	90.9		19	43.2	100.0
2010	54	92.6	1.9	25	46.3	100.0
2011	54	68.5	3.7	15	27.8	93.3
1998-2011	551	90.7	4.4	331	60.1	97.6

Table 10b

Annual cohorts of incident cancers and deaths, proportion of death certificates
and cases deceased the same year of cancer diagnosis
(incl. DCO)
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.52 m as of 2007, respectively)

Year of diagnosis/ death	Incident cases n	Deaths n	Prop. deaths with death certific. %	Deaths in same year n	Prop. deaths in same year %
1998	14	12	91.7		
1999	22	11	90.9	1	4.5
2000	13	18	100.0	3	23.1
2001	19	16	93.8	4	21.1
2002	34	20	100.0		
2003	42	24	91.7	10	23.8
2004	48	29	100.0	10	20.8
2005	53	26	100.0	7	13.2
2006	51	47	97.9	12	23.5
2007	52	33	97.0	7	13.5
2008	51	29	96.6	12	23.5
2009	44	35	100.0	4	9.1
2010	54	38	100.0	10	18.5
2011	54	45	100.0	4	7.4
1998-2011	551	383	97.9	84	15.2

Table 10c

Annual cohorts of deaths, proportion of cancer-related and not cancer-
related deaths, and cancer recorded on death certificates
(incl. DCO)
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.52 m as of 2007, respectively)

Year of death	Deaths n	Prop. cancer-related %	Prop. not cancer-related %	Prop. cancer recorded on death certificate %
1998	12	75.0	25.0	90.9
1999	11	72.7	27.3	90.0
2000	18	66.7	33.3	72.2
2001	16	75.0	25.0	93.3
2002	20	95.0	5.0	100.0
2003	24	62.5	37.5	90.9
2004	29	93.1	6.9	96.6
2005	26	96.2	3.8	96.2
2006	47	89.4	10.6	95.7
2007	33	81.8	18.2	90.6
2008	29	82.8	17.2	96.4
2009	35	85.7	14.3	91.4
2010	38	89.5	10.5	94.7
2011	45	84.4	15.6	91.1
1998-2011	383	84.1	15.9	92.8

Table 11a

Means of age at death according to the grouping in Table 10
MALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (not cancer-related) Years	Age at death (according to death certificate) Years
1998	8	60.6	58.9	65.7	59.8
1999	8	61.1	60.1	64.2	60.0
2000	16	66.2	64.3	69.3	63.9
2001	12	61.1	58.0	76.6	59.5
2002	15	62.1	61.7	67.3	62.1
2003	21	61.7	62.4	60.2	62.2
2004	23	65.0	64.1	86.1	64.1
2005	19	64.2	63.9	70.1	63.9
2006	33	66.0	65.4	69.4	65.6
2007	26	61.9	61.6	64.9	62.2
2008	24	63.3	63.6	61.4	62.5
2009	29	63.7	63.4	65.7	63.8
2010	27	66.9	67.1	61.7	66.9
2011	37	66.9	65.3	76.9	65.9
1998-2011	298	64.2	63.7	67.6	63.8

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11b

Means of age at death according to the grouping in Table 10
FEMALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (not cancer-related) Years	Age at death (according to death certificate) Years
1998	4	64.8	58.0	85.2	64.8
1999	3	60.6	55.9	70.0	60.6
2000	2	71.4	71.4		71.4
2001	4	72.0	59.3	84.7	70.4
2002	5	70.3	70.3		70.3
2003	3	63.0	85.4	51.8	68.4
2004	6	64.7	61.4	81.6	64.7
2005	7	61.9	61.9		61.9
2006	14	67.2	67.2		67.2
2007	7	72.0	70.5	74.1	68.7
2008	5	65.2	60.7	71.9	62.2
2009	6	61.7	62.0	60.0	62.0
2010	11	71.2	66.8	83.2	67.6
2011	8	73.2	74.8	68.5	71.5
1998-2011	85	67.6	66.0	73.5	66.6

By 2010, life expectancy for a newborn male in Germany is 77.5 years compared with 82.6 years for his female counterpart.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 12a

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death
MALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	6	0.5	0.60	0.4	0.60	0.4	0.54	0.5	0.53
1999	6	0.5	0.33	0.3	0.32	0.5	0.33	0.5	0.33
2000	10	0.9	1.11	0.5	1.02	0.8	1.08	1.1	1.28
2001	10	0.9	0.83	0.6	0.83	0.8	0.79	0.8	0.72
2002	14	0.8	0.52	0.5	0.53	0.7	0.54	0.9	0.62
2003	14	0.7	0.39	0.5	0.38	0.6	0.38	0.7	0.36
2004	22	1.2	0.67	0.7	0.68	1.0	0.69	1.2	0.76
2005	18	1.0	0.45	0.6	0.39	0.8	0.42	0.9	0.45
2006	28	1.5	0.74	0.8	0.67	1.2	0.67	1.4	0.71
2007	23	1.0	0.55	0.6	0.52	0.9	0.54	1.0	0.56
2008	21	0.9	0.53	0.6	0.50	0.8	0.50	0.9	0.50
2009	25	1.1	0.86	0.7	0.84	0.9	0.83	1.0	0.83
2010	26	1.2	0.68	0.6	0.67	0.9	0.68	1.1	0.70
2011	32	1.4	0.76	0.8	0.78	1.2	0.80	1.4	0.80
1998-2011	255	1.0	0.62	0.6	0.59	0.9	0.60	1.0	0.63

Table 12b

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death
FEMALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	3	0.3	0.75	0.2	1.00	0.2	0.94	0.3	0.90
1999	2	0.2	0.50	0.1	0.56	0.2	0.58	0.2	0.51
2000	2	0.2	0.50	0.1	0.27	0.1	0.31	0.1	0.42
2001	2	0.2	0.29	0.1	0.40	0.2	0.35	0.2	0.37
2002	5	0.3	0.71	0.1	0.60	0.2	0.59	0.2	0.68
2003	1	0.1	0.20	0.0	0.09	0.0	0.11	0.0	0.11
2004	5	0.3	0.33	0.2	0.39	0.2	0.36	0.2	0.36
2005	7	0.4	0.54	0.2	0.64	0.3	0.64	0.3	0.61
2006	14	0.7	1.08	0.4	0.83	0.5	0.95	0.6	0.94
2007	4	0.2	0.40	0.1	0.26	0.1	0.28	0.1	0.30
2008	3	0.1	0.27	0.1	0.29	0.1	0.29	0.1	0.28
2009	5	0.2	0.33	0.1	0.39	0.2	0.36	0.2	0.38
2010	8	0.3	0.50	0.2	0.51	0.3	0.51	0.3	0.50
2011	6	0.3	0.50	0.1	0.36	0.1	0.37	0.2	0.37
1998-2011	67	0.3	0.49	0.1	0.47	0.2	0.48	0.2	0.48

Table 13

Age distribution of age at death (cancer-related) for period 1998-2011
(**incl. multiple primaries**)

Age at death Years	Cases n	%	Cum.%	Males n	%	Cum.%	Females n	%	Cum.%
35-39	2	0.6	0.6	2	0.8	0.8			0.0
40-44	7	2.2	2.8	7	2.7	3.5			0.0
45-49	23	7.1	9.9	17	6.6	10.2	6	9.0	9.0
50-54	35	10.8	20.7	28	10.9	21.1	7	10.4	19.4
55-59	45	13.9	34.7	39	15.2	36.3	6	9.0	28.4
60-64	70	21.7	56.3	56	21.9	58.2	14	20.9	49.3
65-69	48	14.9	71.2	41	16.0	74.2	7	10.4	59.7
70-74	36	11.1	82.4	22	8.6	82.8	14	20.9	80.6
75-79	33	10.2	92.6	27	10.5	93.4	6	9.0	89.6
80-84	12	3.7	96.3	10	3.9	97.3	2	3.0	92.5
85+	12	3.7	100.0	7	2.7	100.0	5	7.5	100.0
All ages	323	100.0		256	100.0		67	100.0	

Included in the statistics are 36.7% multiple primaries in males and 32.4% in females.

Table 14

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2011
(**incl. multiple primaries**)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34			0.0		0.0			
35-39	2		0.1	0.20	0.0		0.5	
40-44	7		0.3	0.50	0.0		0.9	
45-49	17	6	0.9	0.71	0.3	0.43	1.1	0.3
50-54	28	7	1.7	0.48	0.4	0.70	1.0	0.3
55-59	39	6	2.5	0.50	0.4	0.26	0.8	0.1
60-64	56	14	3.7	0.64	0.9	0.78	0.7	0.3
65-69	41	7	3.0	0.73	0.5	0.28	0.4	0.1
70-74	22	14	2.1	0.58	1.1	0.78	0.2	0.2
75-79	27	6	4.0	0.82	0.6	0.40	0.2	0.1
80-84	10	2	2.5	1.00	0.3	0.50	0.1	0.0
85+	7	5	2.5	1.17	0.7	0.83	0.1	0.0
All ages	256	67					0.4	0.1

Mortality						
Raw	1.0	0.62	0.3	0.49
WS	0.6	0.59	0.1	0.47
ES	0.9	0.60	0.2	0.48
BRD-S	1.0	0.63	0.2	0.48

PYLL-70		
per 100,000	9.4	2.0
ES	8.4	1.8
AYLL-70	11.3	11.4

The rates underestimate the prognosis if other synchronous cancers are prognostic unfavorable.

Table 15a

Multiple primaries in deaths in period 1998-2011
MALES

Diagnosis		Total n	Total %↓	Pre n	Pre ←%	Syn-chron ±30d n	Syn-chron ±30d ←%	Post n	Post ←%
C00	Lip	1	0.8					1	100.0
C03-C06	Oral cavity	5	4.0			1	20.0	4	80.0
C09-C10	Oropharynx	10	7.9			1	10.0	9	90.0
C12-C13	Hypopharynx	6	4.8	3	50.0	2	33.3	1	16.7
C15	Oesophagus	12	9.5	5	41.7	1	8.3	6	50.0
C16	Stomach	4	3.2	2	50.0			2	50.0
C17	Small intestine	1	0.8					1	100.0
C18	Colon	5	4.0	1	20.0	1	20.0	3	60.0
C21	Anus/canal	1	0.8	1	100.0				
C22	Liver	2	1.6					2	100.0
C25	Pancreas	5	4.0	2	40.0			3	60.0
C30-C31	Sinuses	1	0.8	1	100.0				
C32	Larynx	11	8.7	7	63.6	1	9.1	3	27.3
C33-C34	Lung	21	16.7	3	14.3	1	4.8	17	81.0
C38,C45	Mesothelioma	1	0.8					1	100.0
C43	Malign. melanoma	1	0.8	1	100.0				
C44	Skin others	7	5.6	2	28.6			5	71.4
C46,C49	Soft tissue	2	1.6	2	100.0				
C50	Breast	1	0.8	1	100.0				
C61	Prostate	6	4.8	3	50.0			3	50.0
C62	Testis	1	0.8	1	100.0				
C64	Kidney	5	4.0	1	20.0	1	20.0	3	60.0
C67	Bladder	5	4.0	3	60.0			2	40.0
C70-C72	CNS cancer	1	0.8	1	100.0				
C73	Thyroid	1	0.8					1	100.0
C76-C79	CUP	8	6.3	6	75.0	2	25.0		
C82-C85	NHL	1	0.8					1	100.0
C91-C96	Leukaemia	1	0.8					1	100.0
All mult. primaries		126	100.0	46	36.5	11	8.7	69	54.8

Multiple primaries with number of cases n<1 are pooled in category "Other primaries".

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 15b

Multiple primaries in deaths in period 1998-2011
FEMALES

Diagnosis	Total n	Total %↓	Pre n	Pre ←%	Syn-chron ±30d n	Syn-chron ±30d ←%	Post n	Post ←%
C03-C06 Oral cavity	1	3.6					1	100.0
C09-C10 Oropharynx	5	17.9			1	20.0	4	80.0
C12-C13 Hypopharynx	2	7.1			1	50.0	1	50.0
C15 Oesophagus	3	10.7	1	33.3			2	66.7
C25 Pancreas	1	3.6					1	100.0
C32 Larynx	4	14.3	1	25.0	2	50.0	1	25.0
C33-C34 Lung	6	21.4			1	16.7	5	83.3
C44 Skin others	1	3.6	1	100.0				
C50 Breast	1	3.6					1	100.0
C54 Corpus uteri	1	3.6	1	100.0				
C76-C79 CUP	3	10.7	3	100.0				
All mult. primaries	28	100.0	7	25.0	5	17.9	16	57.1

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2011
(**Singular primaries only ***)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34			0.0		0.0			
35-39	1		0.0	0.13	0.0		0.3	
40-44	6		0.3	0.55	0.0		0.9	
45-49	12	6	0.6	0.60	0.3	0.46	0.9	0.4
50-54	27	5	1.6	0.50	0.3	0.71	1.1	0.2
55-59	31	6	2.0	0.46	0.4	0.29	0.7	0.2
60-64	44	10	2.9	0.65	0.6	0.63	0.7	0.2
65-69	35	4	2.6	0.73	0.3	0.21	0.4	0.1
70-74	15	11	1.5	0.52	0.9	0.69	0.2	0.2
75-79	17	6	2.5	1.00	0.6	0.43	0.2	0.1
80-84	8	1	2.0	1.33	0.1	0.33	0.1	0.0
85+	5	4	1.8	1.25	0.5	2.00	0.1	0.0
All ages	201	53					0.4	0.1
Mortality								
Raw			0.8	0.60	0.2	0.46		
WS			0.5	0.58	0.1	0.44		
ES			0.7	0.59	0.2	0.45		
BRD-S			0.8	0.62	0.2	0.45		
PYLL-70								
per 100,000			7.7		1.7			
ES			6.9		1.5			
AYLL-70			11.2		12.3			

* See corresponding tables with multiple primaries.

Table 17

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2011
(**Single primaries only ***)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34			0.0		0.0			
35-39	1		0.0	0.13	0.0		0.3	
40-44	5		0.2	0.50	0.0		0.8	
45-49	8	4	0.4	0.57	0.2	0.33	0.6	0.3
50-54	23	5	1.4	0.48	0.3	0.83	1.0	0.3
55-59	26	5	1.7	0.43	0.3	0.26	0.6	0.2
60-64	37	8	2.4	0.63	0.5	0.57	0.6	0.2
65-69	27	4	2.0	0.60	0.3	0.24	0.4	0.1
70-74	11	8	1.1	0.42	0.6	0.53	0.1	0.1
75-79	13	5	1.9	0.81	0.5	0.36	0.2	0.1
80-84	5	1	1.2	0.83	0.1	1.00	0.1	0.0
85+	5	3	1.8	1.25	0.4	1.50	0.1	0.0
All ages	161	43					0.3	0.1
Mortality								
Raw			0.6	0.54	0.2	0.42		
WS			0.4	0.52	0.1	0.39		
ES			0.5	0.53	0.1	0.40		
BRD-S			0.6	0.55	0.1	0.40		
PYLL-70								
per 100,000			6.3		1.4			
ES			5.6		1.2			
AYLL-70			11.2		11.9			

* See corresponding tables with multiple primaries.

Figure 18. Distribution of age at death (bars) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).

The difference between age at diagnosis (Table 3) and age at base of tongue cancer-related death (see Table 10) should be considered.

Average mortality (world standard population) 2003 - 2008: Males

Average mortality (world standard population) 2003 - 2008: Females

Figure 19a. Map of cancer mortality (world standard population) by county averaged for period 2003 to 2008. According to their individual mortality rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.6/100,000 WS N=121, females 0.1/100,000 WS N=33). Since cancer data are not available in some counties until 2007, the local mortality rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 0 women died from base of tongue cancer. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.0/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 1.4/100,000.

Standardized mortality ratio (SMR) 2003 - 2008: Males

Standardized mortality ratio (SMR) 2003 - 2008: Females

Figure 19b. Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SMR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=121, females N=33). Since cancer data are not available in some counties until 2007, the local SMR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 0 women died from base of tongue cancer. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 0.00. Though, the value of this parameter may vary with an underlying probability of 99% between 0.00 and 5.32, and is therefore not statistically striking.

Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

1. **All multiple primaries included**

   The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. **First singular primary** (no information about other prior or synchronous malignancy)

   The mortality statistic describes the tumor-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

3. **Single primary** (no information about other prior, syn- or metachronous malignancy)

   The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head/neck and lung).

The index from mortality and incidence (Mortality-Incidence ratio, **MI-index**) is a statistic that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MI- index. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

Shortcuts

AYLL-70	Average years of life lost prior to age 70 given a person dies before that age
BRD-S	German standard population
DCO	Death certificate only
EAR	Excess absolute risk = excess cancer cases (O - E) per 10,000 person-years
ES	European standard population (old)
FRG	Federal Republic of Germany
GEKID	Association of Population-based Cancer Registries in Germany (Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)
LCL	Lower confidence limit
MI-index	Ratio between mortality and incidence
MCR	Munich Cancer Registry (Tumorregister München)
PYLL-70	Potential years of life lost prior to age 70 given a person dies before that age
SEER	Surveillance, Epidemiology, and End Results (USA)
SIR	Standardized incidence ratio
SMR	Standardized mortality ratio
UCL	Upper confidence limit
WS	World standard population

Recommended Citation

Munich Cancer Registry. Baseline statistics C01: Base of tongue cancer [Internet]. 2013 [updated 2013 Apr 2; cited 2013 Jun 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/base/base_C01__E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables